Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD),

Director of the U.S. Department of Homeland Security Center of Excellence for
Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM,
Ph.D., to Present Programs to Reduce - Influenza Spread

2nd International Conference on Biodefense and Natural Disasters Meeting in
Orlando, Florida

PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE
MKT:HEB) announced that one of its advanced stage biological products, Alferon
N^®, will be featured as part of a new experimental program designed to
potentially limit the spread and lethality of the pandemic influenza virus
designated H7N9. Professor Richt, Director of the U.S. Department of Homeland
Security Center of Excellence for Emerging and Zoonotic Animal Diseases
(CEEZAD), will present his program to potentially reduce the spread of
influenza from animals to man. Professor Richt, who is a scientific adviser to
Hemispherx Biopharma, will discuss new experiments on the possible inhibition
of Tamiflu-resistant H7N9 virus by Alferon N^® and the potential use of
Alferon^® LDO (a low dose oral formulation of Alferon N^®) in animals that are
considered "mixing vessels" in that they support potential influenza
reassortment and virulence.The conference will take place at the Holiday Inn,
Orlando International Airport, on August 21-23.

About Alferon N^®

Alferon N^® is the only natural source, multi-species alpha interferon
currently approved for sale in the U.S. for the intralesional (within lesions)
treatment of refractory (resistant to other treatment) or recurring external
genital warts (human papilloma virus "HPV") in patients 18 years of age or

About Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD),
Kansas State University

CEEZAD, Center of Excellence for Emerging and Zoonotic Animal Diseases, was
officially inaugurated in June 2010, with its first annual conference, held in
Manhattan, Kansas, home of Kansas State University. CEEZAD was formed to
enhance the capability of the US Department of Homeland Security (DHS) by
developing "state of the art" countermeasures for high priority emerging and
zoonotic animal diseases.

The College of Veterinary Medicine at Kansas State University was established
in 1905. Since then more than 5,000 men and women have been granted the Doctor
of Veterinary Medicine degree. Departments within the College of Veterinary
Medicine are anatomy and physiology, clinical sciences, diagnostic

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company
engaged in the manufacture and clinical development of new drug entities for
treatment of seriously debilitating disorders.Hemispherx's flagship products
include Alferon N Injection® and the experimental therapeutics Ampligen® and
Alferon® LDO.Ampligen® is an experimental RNA nucleic acid being developed
for globally important debilitating diseases and disorders of the immune
system, including Chronic Fatigue Syndrome.Hemispherx's platform technology
includes components for potential treatment of various severely debilitating
and life threatening diseases.Because both Ampligen® and Alferon® LDO are
experimental in nature, they are not designated safe and effective by a
regulatory authority for general use and are legally available only through
clinical trials.Hemispherx has patents comprising its core intellectual
property estate and a fully commercialized product (Alferon N Injection®),
approved for sale in the U.S. and Argentina.The Company's Alferon N approval
in Argentina includes the use of Alferon N Injection (under the brand name
"Naturaferon") for use in any patients who fail, or become intolerant to
recombinant interferon, including patients with chronic active hepatitis C
infection.The Company wholly owns and exclusively operates a GMP certified
manufacturing facility in the United States for commercial products. For more
information please visit

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.Words such as "potential," "potentially," "possible," and similar
expressions are intended to identify forward-looking statements.The inclusion
of forward-looking statements should not be regarded as a representation by
Hemispherx that any of its plans will be achieved.These forward-looking
statements are neither promises nor guarantees of future performance, and are
subject to a variety of risks and uncertainties, many of which are beyond
Hemispherx's control, which could cause actual results to differ materially
from those contemplated in these forward-looking statements.Examples of such
risks and uncertainties include those set forth in the Disclosure Notice,
above, as well as the risks described in Hemispherx's filings with the
Securities and Exchange Commission, including the most recent reports on Forms
10-K, 10-Q and 8-K.You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof, and
Hemispherx undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new information,
future events or circumstances or otherwise revise or update this release to
reflect events or circumstances after the date hereof.

CONTACT: Company/Investor Contact:
         Dianne Will
         Hemispherx Biopharma, Inc.
Press spacebar to pause and continue. Press esc to stop.